NEW YORK (GenomeWeb News) – Roche subsidiary Genentech will use Horizon Discovery's mutant-and-normal cell lines in its oncology drug research programs under a three year agreement, Horizon said today.

The agreement, which expands an ongoing relationship between the companies, will give Genentech access to Horizon's X-MAN cell-line library.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.